Brian K Whisenant

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3819319/publications.pdf

Version: 2024-02-01

| | | 172457 | 161849 |
|----------|----------------|--------------|----------------|
| 57 | 13,279 | 29 | 54 |
| papers | citations | h-index | g-index |
| | | | |
| | | | |
| | | | |
| 57 | 57 | 57 | 8963 |
| all docs | docs citations | times ranked | citing authors |
| | | | |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Rationale and design of the SMall Annuli Randomized To Evolut or SAPIEN Trial (SMART Trial). American Heart Journal, 2022, 243, 92-102. | 2.7 | 18 |
| 2 | Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial. European Heart Journal, 2022, 43, 1639-1648. | 2.2 | 14 |
| 3 | Left Ventricular Hypertrophy and Biomarkers of Cardiac Damage and Stress in Aortic Stenosis. Journal of the American Heart Association, 2022, 11, e023466. | 3.7 | 12 |
| 4 | Left Atrial Appendage Closure Review: Addressing Unmet Needs of AF Mediated Stroke Prevention with Evolving Science. Structural Heart, 2021, 5, 3-10. | 0.6 | 1 |
| 5 | Transcatheter mitral valve in ring, hazards of long anterior mitral leaflet and 3â€dimensional rings. Catheterization and Cardiovascular Interventions, 2021, 97, 353-358. | 1.7 | 2 |
| 6 | 3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1029-1040. | 2.8 | 113 |
| 7 | Tip-to-Base LAMPOON for Transcatheter Mitral Valve Replacement With a Protected Mitral Annulus. JACC: Cardiovascular Interventions, 2021, 14, 541-550. | 2.9 | 17 |
| 8 | 1-Year Outcomes following Bioprosthetic Valve Fracture to Facilitate Valve-in-Valve Transcatheter Aortic Valve Replacement. Structural Heart, 2021, 5, 312-318. | 0.6 | 6 |
| 9 | Prospective Study of TMVR Using Balloon-Expandable Aortic Transcatheter Valves in MAC. JACC: Cardiovascular Interventions, 2021, 14, 830-845. | 2.9 | 49 |
| 10 | Preventing Coronary Obstruction During Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 941-948. | 2.9 | 55 |
| 11 | Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021, 77, 2263-2273. | 2.8 | 19 |
| 12 | Bioprosthetic Valve Fracture: A Practical Guide to Facilitate Valve-In-Valve TAVR. Operative Techniques in Thoracic and Cardiovascular Surgery, 2021, , . | 0.3 | 1 |
| 13 | Bioprosthetic valve fracture: a practical guide. Annals of Cardiothoracic Surgery, 2021, 10, 564-570. | 1.7 | 16 |
| 14 | Pulmonary Artery Dilation. JACC: Cardiovascular Interventions, 2021, 14, 2570-2571. | 2.9 | 0 |
| 15 | One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart Valve. JAMA Cardiology, 2020, 5, 1245. | 6.1 | 115 |
| 16 | Management and Outcomes of Transvenous Pacing Leads in PatientsÂUndergoing Transcatheter Tricuspid Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 2012-2020. | 2.9 | 24 |
| 17 | Technical Considerations and Pitfalls of BASILICA: Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent latrogenic Coronary Artery Obstruction. Structural Heart, 2020, 4, 169-178. | 0.6 | 2 |
| 18 | Severe mitral regurgitation: does one size fit all?. Heart, 2020, 106, 872-873. | 2.9 | 1 |

| # | Article | IF | CITATIONS |
|----|---|-------------------|---------------|
| 19 | Thirty-Day Outcomes of Transcatheter Mitral Valve Replacement for Degenerated Mitral Bioprostheses (Valve-in-Valve), Failed Surgical Rings (Valve-in-Ring), and Native Valve With Severe Mitral Annular Calcification (Valve-in-Mitral Annular Calcification) in the United States. Circulation: Cardiovascular Interventions, 2020, 13, e008425. | 3.9 | 146 |
| 20 | Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves. European Heart Journal, 2020, 41, 2731-2742. | 2.2 | 97 |
| 21 | 2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of MitralÂRegurgitation. Journal of the American College of Cardiology, 2020, 75, 2236-2270. | 2.8 | 132 |
| 22 | Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. New England Journal of Medicine, 2020, 382, 799-809. | 27.0 | 520 |
| 23 | Transcatheter Aortic Valve-in-Valve Replacement for Degenerated Stentless Bioprosthetic Aortic Valves. JACC: Cardiovascular Interventions, 2019, 12, 1217-1226. | 2.9 | 22 |
| 24 | Echocardiographic Outcomes After Transcatheter Leaflet Approximation inÂPatients With Secondary MitralÂRegurgitation. Journal of the American College of Cardiology, 2019, 74, 2969-2979. | 2.8 | 161 |
| 25 | Safety and Efficacy of Periprocedural Heparin Plus a Short-Term Infusion of Tirofiban Versus Bivalirudin Monotherapy in Patients Who Underwent Percutaneous Coronary Intervention (from the) Tj ETQq1 1 | . 0.784314 1.6 | 1 rgBT /Overl |
| 26 | Complications of Bioprosthetic Valve Fracture as an Adjunct to Valve-in-Valve TAVR. Structural Heart, 2019, 3, 92-99. | 0.6 | 18 |
| 27 | Bioprosthetic valve fracture: Technical insights from a multicenter study. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 1317-1328.e1. | 0.8 | 81 |
| 28 | Volume and the Ever-Increasing Standard of Quality Heart Valve Care. JACC: Cardiovascular Interventions, 2019, 12, 98-99. | 2.9 | 1 |
| 29 | Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. European Heart Journal, 2019, 40, 441-451. | 2.2 | 271 |
| 30 | 1-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Mitral Annular Calcification. Journal of the American College of Cardiology, 2018, 71, 1841-1853. | 2.8 | 288 |
| 31 | Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry. European Heart Journal, 2018, 39, 687-695. | 2.2 | 269 |
| 32 | Transcatheter Mitral-Valve Repair in Patients with Heart Failure. New England Journal of Medicine, 2018, 379, 2307-2318. | 27.0 | 2,079 |
| 33 | Transcatheter Mitral Valve Implantation in Degenerated Bioprosthetic Valves. Journal of the American Society of Echocardiography, 2018, 31, 845-859. | 2.8 | 4 |
| 34 | Early Outcomes of Percutaneous Transvenous Transseptal Transcatheter Valve Implantation in Failed Bioprosthetic Mitral Valves, Ring Annuloplasty, andÂSevere Mitral Annular Calcification. JACC: Cardiovascular Interventions, 2017, 10, 1932-1942. | 2.9 | 131 |
| 35 | Transcatheter Mitral Valve Replacement for Degenerated Bioprosthetic Valves andÂFailedÂAnnuloplasty Rings. Journal of the American College of Cardiology, 2017, 70, 1121-1131. | 2.8 | 183 |
| 36 | PFO and Migraine. Journal of the American College of Cardiology, 2017, 70, 2775-2777. | 2.8 | 5 |

| # | Article | IF | CITATIONS |
|----|---|--------------------|----------------------|
| 37 | Abstract 23079: Clinical Outcomes of Transcatheter Mitral Valve Replacement for Degenerated Mitral Bioprostheses (Mitral Valve-in-Valve) and Surgical Rings (Mitral Valve-in-Ring) in the United States: Data From the STS/ACC/TVT Registry. Circulation, 2017, 136, . | 1.6 | 0 |
| 38 | Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. New England Journal of Medicine, 2016, 374, 1609-1620. | 27.0 | 3,992 |
| 39 | Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet, The, 2016, 387, 2218-2225. | 13.7 | 899 |
| 40 | Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. European Heart Journal, 2016, 37, 2252-2262. | 2.2 | 305 |
| 41 | From Good to Great. JACC: Cardiovascular Interventions, 2016, 9, 2341-2342. | 2.9 | 3 |
| 42 | One-Year Clinical Outcomes With SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Severe Aortic Stenosis. Circulation, 2016, 134, 130-140. | 1.6 | 172 |
| 43 | In vitro evaluation of implantation depth in valve-in-valve using different transcatheter heart valves. EuroIntervention, 2016, 12, 909-917. | 3.2 | 49 |
| 44 | Effect of Tricuspid Regurgitation and the Right Heart on Survival After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, $2015, 8, .$ | 3.9 | 148 |
| 45 | A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients With Aortic Stenosis Who Are NotÂCandidates for Surgery. JACC: Cardiovascular Interventions, 2015, 8, 1797-1806. | 2.9 | 90 |
| 46 | Thrombosis following mitral and tricuspid valve-in-valve replacement. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, e26-e29. | 0.8 | 25 |
| 47 | Left Atrial Appendage Occlusion Addresses the Tremendous Unmet Needs of Stroke Prevention in Atrial Fibrillation That Persist Despite Recent Advances in Anticoagulation Therapy. Circulation, 2014, 130, 1516-1523. | 1.6 | 8 |
| 48 | Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2014, 312, 1988. | 7.4 | 765 |
| 49 | Left Atrial Appendage Closure with Transcatheter-Delivered Devices. Interventional Cardiology Clinics, 2014, 3, 209-218. | 0.4 | 16 |
| 50 | Stratification of Outcomes After Transcatheter AorticÂValve Replacement According to Surgical Inoperability for Technical Versus Clinical Reasons. Journal of the American College of Cardiology, 2014, 63, 901-911. | 2.8 | 62 |
| 51 | Outcomes After Transfemoral Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2014, 7, 1245-1251. | 2.9 | 27 |
| 52 | Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy. Journal of the American College of Cardiology, 2014, 64, 1-12. | 2.8 | 1,605 |
| 53 | The relative performance characteristics of the logistic European System for Cardiac Operative Risk Evaluation score and the Society of Thoracic Surgeons score in the Placement of Aortic Transcatheter Valves trial. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2830-2837.e1. | 0.8 | 62 |
| 54 | Quality of Life Assessment in the Randomized PROTECT AF (Percutaneous Closure of the Left Atrial) Tj ETQq0 0 Conference of Patients at Risk for Stroke With Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 1790-1798. | 0 rgBT /Ove 2.8 | erlock 10 Tf 5 96 |

4

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Usefulness of Left Atrial Appendage Volume as a Predictor of Embolic Stroke in Patients With Atrial Fibrillation. American Journal of Cardiology, 2013, 112, 1148-1152. | 1.6 | 57 |
| 56 | Device closure of paravalvular defects following transcatheter aortic valve replacement with the Edwards Sapien valve. Catheterization and Cardiovascular Interventions, 2013, 81, 901-905. | 1.7 | 23 |
| 57 | Severe Mitral Regurgitation: More than Pulmonary Congestion. Structural Heart, 0, , 1-2. | 0.6 | 0 |